Marta Romano

List of Publications by Year
in descending order

42 papers	1,429 citations	331670 21 h-index	330143 37 g-index
43 all docs	43 docs citations	43 times ranked	2255 citing authors

#	Article	IF	Citations
1	Early high antibody titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma. European Respiratory Journal, 2022, 59, 2101724.	6.7	38
2	Efficacy and safety of camostat mesylate in early COVID-19 disease in an ambulatory setting: a randomized placebo-controlled phase II trial. International Journal of Infectious Diseases, 2022, 122, 628-635.	3.3	14
3	<i>Aspergillus</i> <i>fumigatus</i>Recognition by Dendritic Cells Negatively Regulates Allergic Lung Inflammation through a TLR2/MyD88 Pathway. American Journal of Respiratory Cell and Molecular Biology, 2021, 64, 39-49.	2.9	10
4	In-vivo expressed Mycobacterium tuberculosis antigens recognised in three mouse strains after infection and BCG vaccination. Npj Vaccines, 2021, 6, 81.	6.0	8
5	Lentiviral vector induces high-quality memory T cells via dendritic cells transduction. Communications Biology, 2021, 4, 713.	4.4	17
6	SARS-CoV-2 neutralising antibody testing in Europe: towards harmonisation of neutralising antibody titres for better use of convalescent plasma and comparability of trial data. Eurosurveillance, 2021, 26, .	7.0	31
7	Progressive Control of Streptococcus agalactiae-Induced Innate Inflammatory Response Is Associated with Time Course Expression of MicroRNA-223 by Neutrophils. Infection and Immunity, 2020, 88, .	2.2	8
8	The global response to the COVID-19 pandemic: how have immunology societies contributed?. Nature Reviews Immunology, 2020, 20, 594-602.	22.7	17
9	A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. Trials, 2020, 21, 981.	1.6	17
10	Allergic Asthma Favors Brucella Growth in the Lungs of Infected Mice. Frontiers in Immunology, 2018, 9, 1856.	4.8	21
11	Relationship between mold exposure, specific IgE sensitization, and clinical asthma. Annals of Allergy, Asthma and Immunology, 2018, 121, 333-339.	1.0	13
12	Development of a Dot-Blot Assay for the Detection of Mould-Specific IgE in the Belgian Population. Mycopathologia, 2017, 182, 319-329.	3.1	4
13	Inflammatory Properties and Adjuvant Potential of Synthetic Glycolipids Homologous to Mycolate Esters of the Cell Wall of <i>Mycobacterium tuberculosis</i>. Journal of Innate Immunity, 2017, 9, 162-180.	3.8	28
14	Trypanosoma Infection Favors Brucella Elimination via IL-12/IFNÎ^{3}-Dependent Pathways. Frontiers in Immunology, 2017, 8, 903.	4.8	25
15	Differential Susceptibility to Infectious Respiratory Diseases between Males and Females Linked to Sex-Specific Innate Immune Inflammatory Response. Frontiers in Immunology, 2017, 8, 1806.	4.8	40
16	Synthesis of wax esters and related trehalose esters from Mycobacterium avium and other mycobacteria. Tetrahedron, 2016, 72, 3863-3876.	1.9	7
17	Innate signaling by mycobacterial cell wall components and relevance for development of adjuvants for subunit vaccines. Expert Review of Vaccines, 2016, 15, 1409-1420.	4.4	7
18	Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial. Lancet Respiratory Medicine,the, 2015, 3, 190-200.	10.7	122

#	Article	IF	Citations
19	Overexpression of DosR in Mycobacterium tuberculosis does not affect aerobic replication in vitro or in murine macrophages. Annals of Microbiology, 2015, 65, 713-720.	2.6	4
20	Increased B and T Cell Responses in M. bovis Bacille Calmette-GuÃ©rin Vaccinated Pigs Co-Immunized with Plasmid DNA Encoding a Prototype Tuberculosis Antigen. PLoS ONE, 2015, 10, e0132288.	2.5	5
21	Novel GMO-Based Vaccines against Tuberculosis: State of the Art and Biosafety Considerations. Vaccines, 2014, 2, 463-499.	4.4	3
22	DNA vaccines against tuberculosis. Expert Opinion on Biological Therapy, 2014, 14, 1801-1813.	3.1	30
23	Increasing the Vaccine Potential of Live M. bovis BCG by Coadministration with Plasmid DNA Encoding a Tuberculosis Prototype Antigen. Vaccines, 2014, 2, 181-195.	4.4	15
24	Mice genetically inactivated in interleukinâ€17<scp>A</scp> receptor are defective in longâ€term control of <i><scp>M</scp>ycobacterium tuberculosis</i> infection. Immunology, 2013, 140, 220-231.	4.4	61
25	Clinical value of IS6110-based loop-mediated isothermal amplification for detection of Mycobacterium tuberculosis complex in respiratory specimens. Journal of Infection, 2013, 66, 487-493.	3.3	27
26	Immunogenicity of eight Mycobacterium avium subsp. paratuberculosis specific antigens in DNA vaccinated and Map infected mice. Veterinary Immunology and Immunopathology, 2012, 145, 74-85.	1.2	17
27	An update on vaccines for tuberculosis â€“ there is more to it than just waning of BCG efficacy with time. Expert Opinion on Biological Therapy, 2012, 12, 1601-1610.	3.1	24
28	Experimental Tuberculosis in the Wistar Rat: A Model for Protective Immunity and Control of Infection. PLoS ONE, 2011, 6, e18632.	2.5	39
29	Increased Pulmonary Tumor Necrosis Factor Alpha, Interleukin-6 (IL-6), and IL-17A Responses Compensate for Decreased Gamma Interferon Production in Anti-IL-12 Autovaccine-Treated, Mycobacterium bovis BCG-Vaccinated Mice. Vaccine Journal, 2011, 18, 95-104.	3.1	17
30	A novel and more sensitive loop-mediated isothermal amplification assay targeting IS6110 for detection of Mycobacterium tuberculosis complex. Microbiological Research, 2010, 165, 211-220.	5.3	135
31	DNA vaccines against mycobacterial diseases. Expert Review of Vaccines, 2009, 8, 1237-1250.	4.4	26
32	Liver X receptors contribute to the protective immune response against Mycobacterium tuberculosis in mice. Journal of Clinical Investigation, 2009, 119, 1626-1637.	8.2	138
33	Immunogenicity and protective efficacy of a tuberculosis DNA vaccine co-expressing pro-apoptotic caspase-3. Vaccine, 2008, 26, 1458-1470.	3.8	14
34	Immunogenicity and protective efficacy of DNA vaccines encoding MAP0586c and MAP4308c of Mycobacterium avium subsp. paratuberculosis secretome. Vaccine, 2008, 26, 4783-4794.	3.8	24
35	Immunogenicity and protective efficacy of tuberculosis subunit vaccines expressing PPE44 (Rv2770c). Vaccine, 2008, 26, 6053-6063.	3.8	43
36	Immunogenicity of Eight Dormancy Regulon-Encoded Proteins of Mycobacterium tuberculosis in DNA-Vaccinated and Tuberculosis-Infected Mice. Infection and Immunity, 2007, 75, 941-949.	2.2	138

#	Article	IF	Citations
37	Evaluation of the immunogenicity of pBudCE4.1 plasmids encoding mycolyl-transferase Ag85A and phosphate transport receptor PstS-3 from Mycobacterium tuberculosis. Vaccine, 2006, 24, 4640-4643.	3.8	18
38	Priming but not boosting with plasmid DNA encoding mycolyl-transferase Ag85A from Mycobacterium tuberculosis increases the survival time of Mycobacterium bovis BCG vaccinated mice against low dose intravenous challenge with M. tuberculosis H37Rv. Vaccine, 2006, 24, 3353-3364.	3.8	81
39	Immunogenicity and protective efficacy of tuberculosis DNA vaccines combining mycolyl-transferase Ag85A and phosphate transport receptor PstS-3. Immunology, 2006, 118, 321-332.	4.4	30
40	Partial Reconstitution of the CD4+-T-Cell Compartment in CD4 Gene Knockout Mice Restores Responses to Tuberculosis DNA Vaccines. Infection and Immunity, 2006, 74, 2751-2759.	2.2	13
41	Induction of In Vivo Functional Db-Restricted Cytolytic T Cell Activity against a Putative Phosphate Transport Receptor ofMycobacterium tuberculosis. Journal of Immunology, 2004, 172, 6913-6921.	0.8	35
42	The Schizosaccharomyces pombe protein Yab8p and a novel factor, Yip1p, share structural and functional similarity with the spinal muscular atrophy-associated proteins SMN and SIP1. Human Molecular Genetics, 2000, 9, 663-674.	2.9	64